Vimarsana
Biggest News Aggregation in the World

Emerging Science Session News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Emerging Science Session. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Emerging Science Session Today - Breaking & Trending Today

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15 - Vimarsana News

Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15

PACIFIC Study Phase 1b/2a clinical data to be featured in a podium presentation at an Emerging Science Session at the AAN Annual Meeting Data will be featured in an encore presentation at the...

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug - Vimarsana News

The 'Penicillin' of Antivirals, Xafty by Hyundai Bioscience, Opened a New Era of Treating Respiratory Viral Infections with Single Drug

/PRNewswire/ -- The result of clinical study for EUA (emergency use authorization) on COVID-19 with Xafty™ (CP-COV03) was presented at the 'Emerging Science'...

New Phase 3 Trial Data Show Eplontersen Improved Neuropathy in Over Half of Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy - Vimarsana News

New Phase 3 Trial Data Show Eplontersen Improved Neuropathy in Over Half of Patients With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

Study shows eplontersen maintains a consistent and sustained treatment effect and reinforces its potential treating hereditary transthyretin-mediated amyloid polyneuropathy, which can lead to heart failure.

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks - Vimarsana News

NEURO-TTRansform Phase III results presented at AAN showed eplontersen demonstrated consistent and sustained improvement in all measures of disease and quality of life through 66 weeks

Eplontersen halted neuropathy disease progression and improved neuropathy impairment and quality of life ... | June 18, 2023

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022 - Vimarsana News

Neurocrine Biosciences Presents Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at AAN 2022

- Valbenazine Met the Primary Endpoint of Significant (p<0.0001) Improvement in Chorea Severity versus Placebo as Measured by the Unified Huntington's Disease...